|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
3.300 -0.080 (-2.367%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Turnover | 15,874,403 | 3.910% | 15,277,037 | 15,193,738 | 14,353,781 | 12,647,775 |
| Cost of Sales | (2,844,780) | -12.643% | (3,256,505) | (2,959,599) | (2,753,121) | (2,792,044) |
| Gross Profit | 13,029,623 | 8.395% | 12,020,532 | 12,234,139 | 11,600,660 | 9,855,731 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (93,056) | -57.593% | (219,438) | 503,155 | 7,584,980 | (41,188) | |
| Profit / (Loss) before Taxation | 3,614,016 | 12.091% | 3,224,167 | 3,754,612 | 10,978,515 | 2,610,452 | |
| Taxation | (614,093) | 17.027% | (524,743) | (571,391) | (1,336,911) | (546,325) | |
| Profit / (Loss) from Discontinued Operations | 1,606,765 | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,589,526) | 10.335% | (1,440,640) | (1,262,184) | (1,161,264) | (823,515) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,017,162 | 139.689% | 1,258,784 | 1,921,037 | 8,480,340 | 1,240,612 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | 2021/06 RMB(K¥) | 2020/06 RMB(K¥) | |
| Net Finance Costs / (Income) | (70,109) | -- | 115,037 | 46,423 | 47,914 | 21,554 |
| Depreciation & Amortisation | 510,231 | -21.888% | 653,208 | 408,672 | 413,156 | 665,044 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/06 | 2022/06 | 2021/06 | 2020/06 | |
| EPS (cts) | 16.390 | 141.740% | 6.780 | 10.300 | 45.150 | 6.600 |
| DPS (cts) | 2.752 | -- | 1.833 | 5.229 | 3.323 | 2.963 |
| Dividend Payout Ratio (%) | 16.792% | -- | 27.036% | 50.769% | 7.359% | 44.894% |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 1.748 | -- | 1.594 | 1.606 | 1.303 | 1.670 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,017,162 |
| %Change | 139.689% |
| EPS / (LPS) | RMB 0.164 |
| NBV Per Share (¥) | RMB 1.748 |